Cardiogenic Shock After Anterior STEMI
A 58-year-old woman presents 4 hours after onset of substernal chest pain with diaphoresis. ECG shows 3 mm ST elevation in V1–V4 with reciprocal changes. Blood pressure is 82/54 mmHg, heart rate 118 bpm, and she is cool and clammy with altered mentation. She is intubated for respiratory failure. Bedside echo shows an LVEF of 25% with anteroapical akinesis and no significant mitral regurgitation or VSD. Troponin is markedly elevated, lactate is 4.2 mmol/L, and creatinine is 1.8 mg/dL. The cath lab is ready; door-to-balloon time is projected at 70 minutes. She has no prior cardiac history and no contraindications to antiplatelet therapy.
1. What is your immediate management strategy before and during transport to the cath lab?
Read the worked answer
This is STEMI complicated by cardiogenic shock (SCAI stage C). Priorities:
- Revascularization is the definitive therapy - proceed emergently to primary PCI; do not delay for medical optimization beyond minutes.
- Airway and oxygenation: she is already intubated; target SpO2 92–96% and avoid hyperoxia.
- Hemodynamic support: start norepinephrine to target MAP ≥65 mmHg. Avoid fluid loading if there is no hypovolemia; if preload is unclear, a small fluid challenge may be considered but pulmonary edema risk is high.
- Antiplatelet/anticoagulant: give aspirin 325 mg chewed and a P2Y12 inhibitor (ticagrelor or prasugrel if no contraindication; clopidogrel if concern about bleeding or need for surgery). Give unfractionated heparin per weight.
- Mechanical circulatory support: consider an Impella or IABP as a bridge. Evidence (IABP-SHOCK II) does not show routine IABP mortality benefit; use it for mechanical complications or as a bridge. Impella may be considered in selected patients, but routine use is not proven.
- Avoid nephrotoxins and minimize contrast volume.
2. How do you decide between an IABP, Impella, and ECMO in this patient?
Read the worked answer
Decision framework:
- IABP: modest augmentation of diastolic pressure and afterload reduction; best for mechanical complications (acute MR, VSD) or as a bridge. No mortality benefit in routine cardiogenic shock.
- Impella (percutaneous LVAD): provides forward flow and LV unloading; consider if there is severe LV dysfunction with inadequate cardiac output despite vasopressors, or as a bridge to recovery/decision. Risks: hemolysis, limb ischemia, bleeding, and cost. Not proven to reduce mortality in routine use.
- VA-ECMO: for refractory shock with end-organ failure or cardiac arrest; provides full circulatory support but increases LV afterload and can worsen pulmonary edema; often combined with an LV vent (Impella) in a "ECPella" configuration.
For this patient: she has severe LV dysfunction with shock and is being revascularized. A reasonable approach is to proceed with PCI under vasopressor support and place an Impella or IABP if hemodynamics do not improve after revascularization. ECMO is reserved for refractory collapse or cardiac arrest. The choice should be made by a shock team with clear exit criteria.
3. What post-PCI management issues are specific to this presentation?
Read the worked answer
- Reperfusion injury and stunning: LVEF may improve over days to weeks; avoid premature prognostication.
- Right heart and renal function: monitor urine output and creatinine; avoid nephrotoxic drugs and contrast.
- Mechanical complications: repeat echo to exclude VSD, papillary muscle rupture, and free wall rupture, which can present late.
- Antithrombotic therapy: continue DAPT; if a mechanical support device is in place, coordinate anticoagulation to avoid bleeding.
- Ventilation and sedation: wean as tolerated; avoid hypotension from sedatives.
- Prognosis discussion: cardiogenic shock carries high mortality; involve the patient's family and consider goals of care.